

**Probiodrug AG to hold its Ordinary General Meeting of Shareholders  
on 13 June 2017**

**HALLE (SAALE), Germany, 02 May 2017** - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), has the honour to invite its shareholders to its ordinary general meeting of shareholders to be held on 13 June 2017 at 11.00am (CEST), in the Mercure Hotel MOA Berlin, Stephanstraße 41, 10559 Berlin, Germany.

The relevant documents can be found at <http://www.probiodrug.de/investors/annual-shareholders-meeting-2017/>.

###

**For more information, please contact:**

**Probiodrug**

Dr Konrad Glund, CEO

Email: [contact@probiodrug.de](mailto:contact@probiodrug.de)

**Hume Brophy**

Conor Griffin, Jonathan Blackbourn, Alexander Protsenko

Tel: +44 (0) 20 7862 6381

Email: [probiodrug@humbrophy.com](mailto:probiodrug@humbrophy.com)

**The Trout Group**

Tricia Truehart

Tel: +1 (646) 378-2953

Email: [truehart@troutgroup.com](mailto:truehart@troutgroup.com)

**MC Services AG**

Anne Hennecke, Caroline Bergmann

Tel: +49 (0) 211 529 252 20

Email: [probiodrug@mc-services.eu](mailto:probiodrug@mc-services.eu)

**Notes to Editors:**

**About Probiodrug AG**

Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease.

Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.

Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Aβeta (pGlu-Aβeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Aβeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research.

Probiodrug's lead product candidate, PQ912, is a highly specific and potent inhibitor of Glutaminyi Cyclase (QC), which has shown therapeutic effects in Alzheimer's animal models. PQ912 is currently in a Phase 2a study, the SAPHIR trial. In a preceding Phase 1 study with healthy young and elderly volunteers, PQ912 has shown to be safe and well tolerated and also revealed high QC-inhibition.

[www.probiodrug.de](http://www.probiodrug.de)

### **About Alzheimer's disease**

Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer's disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. . Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. Alzheimer's has an estimated, global societal cost of US\$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016).

### **Forward Looking Statements**

*Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*